MX2018011793A - Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. - Google Patents
Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.Info
- Publication number
- MX2018011793A MX2018011793A MX2018011793A MX2018011793A MX2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A MX 2018011793 A MX2018011793 A MX 2018011793A
- Authority
- MX
- Mexico
- Prior art keywords
- antigens
- pharmaceutical composition
- virus
- antigen
- hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000038A CU24454B1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
| PCT/CU2017/050001 WO2017167317A1 (es) | 2016-03-31 | 2017-03-14 | Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011793A true MX2018011793A (es) | 2018-12-17 |
Family
ID=58671308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011793A MX2018011793A (es) | 2016-03-31 | 2017-03-14 | Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11491218B2 (enExample) |
| EP (1) | EP3437654B1 (enExample) |
| JP (1) | JP6981992B2 (enExample) |
| KR (1) | KR20180125985A (enExample) |
| CN (1) | CN109219449B (enExample) |
| AR (1) | AR108009A1 (enExample) |
| AU (1) | AU2017243136B2 (enExample) |
| CU (1) | CU24454B1 (enExample) |
| EA (1) | EA201892212A1 (enExample) |
| ES (1) | ES2965709T3 (enExample) |
| MX (1) | MX2018011793A (enExample) |
| MY (1) | MY202118A (enExample) |
| TW (1) | TWI755383B (enExample) |
| UA (1) | UA128952C2 (enExample) |
| WO (1) | WO2017167317A1 (enExample) |
| ZA (1) | ZA201806325B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022548328A (ja) * | 2019-09-23 | 2022-11-17 | アセンド バイオテクノロジー インク | 生分解性ナノ複合体ワクチン、ｂ型肝炎ウイルス複製およびｂ型肝炎ウイルス表面抗原分泌の抑制方法 |
| JP2023509966A (ja) | 2020-01-10 | 2023-03-10 | カロジェン コーポレイション | 腫瘍溶解性ウイルス様小胞の組成物および使用方法 |
| CU20200028A7 (es) | 2020-04-20 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Nucleoproteína viral y formulaciones que la contienen |
| EP4465999A4 (en) * | 2022-02-22 | 2025-12-24 | Carogen Corp | Polyvalent Virus Vesicle (VLV) Platform for Infectious Diseases and Cancer Immunotherapy Applications |
| CN116218881B (zh) * | 2022-10-21 | 2024-08-13 | 山东大学 | 一种治疗或者预防乙肝病毒的疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22290A1 (es) | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
| CU22871A1 (es) | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CN1164331C (zh) * | 2001-05-23 | 2004-09-01 | 中国人民解放军第二军医大学 | 一种人乙型肝炎核酸疫苗 |
| CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| CN104338132A (zh) * | 2013-07-26 | 2015-02-11 | 复旦大学 | 一种病毒免疫治疗药物复合物及其用途 |
-
2017
- 2017-03-14 EA EA201892212A patent/EA201892212A1/ru unknown
- 2017-03-14 EP EP17721509.2A patent/EP3437654B1/en active Active
- 2017-03-14 ES ES17721509T patent/ES2965709T3/es active Active
- 2017-03-14 UA UAA201810715A patent/UA128952C2/uk unknown
- 2017-03-14 KR KR1020187028749A patent/KR20180125985A/ko not_active Ceased
- 2017-03-14 CU CU2016000038A patent/CU24454B1/es unknown
- 2017-03-14 WO PCT/CU2017/050001 patent/WO2017167317A1/es not_active Ceased
- 2017-03-14 US US16/088,188 patent/US11491218B2/en active Active
- 2017-03-14 MX MX2018011793A patent/MX2018011793A/es unknown
- 2017-03-14 JP JP2018551333A patent/JP6981992B2/ja active Active
- 2017-03-14 CN CN201780033618.XA patent/CN109219449B/zh active Active
- 2017-03-14 AU AU2017243136A patent/AU2017243136B2/en not_active Ceased
- 2017-03-14 MY MYPI2018703588A patent/MY202118A/en unknown
- 2017-03-22 TW TW106109533A patent/TWI755383B/zh not_active IP Right Cessation
- 2017-03-30 AR ARP170100786A patent/AR108009A1/es not_active Application Discontinuation
-
2018
- 2018-09-20 ZA ZA2018/06325A patent/ZA201806325B/en unknown
-
2022
- 2022-03-08 US US17/689,581 patent/US11759517B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CU24454B1 (es) | 2019-11-04 |
| US11759517B2 (en) | 2023-09-19 |
| US20200297840A1 (en) | 2020-09-24 |
| BR112018069738A2 (pt) | 2019-02-05 |
| CU20160038A7 (es) | 2017-11-07 |
| CN109219449A (zh) | 2019-01-15 |
| EP3437654B1 (en) | 2023-09-20 |
| EA201892212A1 (ru) | 2019-03-29 |
| JP6981992B2 (ja) | 2021-12-17 |
| JP2019510064A (ja) | 2019-04-11 |
| KR20180125985A (ko) | 2018-11-26 |
| AR108009A1 (es) | 2018-07-04 |
| WO2017167317A1 (es) | 2017-10-05 |
| AU2017243136B2 (en) | 2022-02-17 |
| CN109219449B (zh) | 2022-08-30 |
| US20220193228A1 (en) | 2022-06-23 |
| TWI755383B (zh) | 2022-02-21 |
| EP3437654A1 (en) | 2019-02-06 |
| ES2965709T3 (es) | 2024-04-16 |
| MY202118A (en) | 2024-04-04 |
| HK1259329A1 (zh) | 2019-11-29 |
| ZA201806325B (en) | 2020-08-26 |
| AU2017243136A1 (en) | 2018-10-11 |
| US11491218B2 (en) | 2022-11-08 |
| TW201735945A (zh) | 2017-10-16 |
| CA3017778A1 (en) | 2017-10-05 |
| UA128952C2 (uk) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011793A (es) | Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b. | |
| PH12019550220A1 (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| PE20160686A1 (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| MX421406B (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas | |
| CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| CL2020001146A1 (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
| JOP20170161B1 (ar) | عوامل RNAi للعدوى بفيروس التهاب الكبد ب | |
| UY37962A (es) | Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
| PH12020550924A1 (en) | Heptatitis b virus (hbv) vaccines and uses thereof | |
| MX2022007908A (es) | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. | |
| AU2017240761A1 (en) | Compositions and methods for enhanced innate immunity | |
| JP2019510064A5 (enExample) | ||
| PH12017500419B1 (en) | Recoded arbovirus and vaccines | |
| WO2018066891A3 (ko) | 인터페론 베타 변이체의 안정화 제제 | |
| AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene | |
| UY31574A1 (es) | Vacunas contra la malaria | |
| RU2017138083A (ru) | Применение полимиксина в качестве антидота при отравлениях аматоксинами | |
| HK40074158A (en) | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines | |
| MX390292B (es) | Vacuna heterologa atenuada viva para leptospira. | |
| HK1216988A1 (zh) | 用於治療單純皰疹病毒2型感染的治療性疫苗 | |
| JO3769B1 (ar) | علاج RNAi لعدوى فيروس التهاب الكبد B |